BRAVO 3 trial results, bivalirudin, heparin, anticoagulation, TAVR, TCT 2015

Results from the BRAVO 3 trial found that bivalirudin did not significantly reduce major bleeding rates at 48 hours or adverse events at 30 days compared to heparin in high-risk patients undergoing transcatheter aortic valve replacement (TAVR).

October 19, 2015 — Vascular Interventional Advances (VIVA) Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced the late-breaking sessions at its annual conference, VIVA 2015. Sixteen trial results, featuring the latest in vascular technology and devices, will be released for the first time Nov. 2-3 at the Wynn Las Vegas.

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.

Amaranth Fortitute Bioresorbable stent

There were several overarching technology trends seen at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco Oct. 11-15. The key technologies emphasized this year included new transcatheter devices in development to treat not only the aortic valve, but also the mitral and tricuspid valves. Bioresorbable stents and bioresorbable drug carrier polymers for metallic stents were heavily highlighted in sessions and on the show floor. Several TCT sessions also centered on the new economic realities hospitals face with pressures of healthcare reform. 
transradial access, TRI, DRAGON trial, TCT 2015, non-inferiority, transfemoral access, TFO

Results from a prospective randomized trial of transradial (TRI) versus transfemoral (TFO) access in patients undergoing percutaneous coronary intervention found that TRI was non-inferior in terms of clinical effectiveness at one year and superior in reducing major bleeding complications at seven days compared to TFI.
FFR-CT, cost and quality of life outcomes, TCT 2015, PLATFORM trial

New results from a multicenter, prospective study show that assessing fractional flow reserve estimated with computed tomography (FFR-CT) may reduce costs in selected symptomatic patients with suspected coronary artery disease (CAD).
IN.PACT SFA study, TCT 2015, drug-coated balloons, PTA, SFA disease, superficial femoral artery
IN.PACT SFA, trial conclusions, TCT 2015

Two-year results from the IN.PACT SFA study found the use of a drug-coated balloon was superior to conventional percutaneous transluminal angioplasty (PTA) in treating patients with superficial femoral artery (SFA) disease.

The main pumping chamber of the heart ages differently in men and women, according to a new magnetic resonance imaging (MRI) study published online in the journal Radiology. Researchers said the findings may support different treatment approaches for men and women with heart disease.

RESPECT trial, long-term study results, TCT 2015, PFO closure, recurrent cryptogenic stroke

Long-term study results from the RESPECT trial found that closing a patent foramen ovale (PFO) with an Amplatzer PFO Occluder was superior to medical management in the prevention of recurrent cryptogenic stroke in patients who had previously experienced one.

October 16, 2015 — Enrollment has successfully concluded in its multi-center, international CE mark clinical trials MEND-II and RENASCENT-I for the assessment of the Amaranth Medical Fortitude sirolimus-eluting bioresorbable scaffold (BRS) in patients with symptomatic coronary artery disease. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now